Partner Communications Company Ltd. (PTNR) Is At $3.72 Formed Wedge; Zafgen (ZFGN) SI Increased By 36.94%

May 17, 2018 - By Jerrie Dane

Zafgen, Inc. (NASDAQ:ZFGN) Logo

Zafgen Inc (NASDAQ:ZFGN) had an increase of 36.94% in short interest. ZFGN’s SI was 622,100 shares in May as released by FINRA. Its up 36.94% from 454,300 shares previously. With 142,100 avg volume, 4 days are for Zafgen Inc (NASDAQ:ZFGN)’s short sellers to cover ZFGN’s short positions. The SI to Zafgen Inc’s float is 2.76%. The stock decreased 1.07% or $0.07 during the last trading session, reaching $6.45. About 48,149 shares traded. Zafgen, Inc. (NASDAQ:ZFGN) has risen 54.27% since May 17, 2017 and is uptrending. It has outperformed by 42.72% the S&P500.

Partner Communications Company Ltd. (PTNR) formed wedge down with $3.50 target or 6.00% below today’s $3.72 share price. Partner Communications Company Ltd. (PTNR) has $626.39 million valuation. The stock decreased 4.12% or $0.16 during the last trading session, reaching $3.72. About 22,606 shares traded or 182.29% up from the average. Partner Communications Company Ltd. (NASDAQ:PTNR) has declined 21.90% since May 17, 2017 and is downtrending. It has underperformed by 33.45% the S&P500.

More recent Zafgen, Inc. (NASDAQ:ZFGN) news were published by: which released: “Zafgen’s (ZFGN) CEO Jeff Hatfield on Q1 2018 Results – Earnings Call Transcript” on May 12, 2018. Also published the news titled: “Zafgen Reports First Quarter 2018 Operating and Financial Results” on May 08, 2018.‘s news article titled: “Zafgen to Host Conference Call to Discuss First Quarter 2018 Financial Results” with publication date: May 01, 2018 was also an interesting one.

Zafgen, Inc., a biopharmaceutical company, focuses on the development of therapeutics for patients suffering from metabolic diseases comprising type 2 diabetes and obesity. The company has market cap of $177.78 million. The companyÂ’s lead product candidate is ZGN-1061, a fumagillin-class MetAP2 inhibitor administered by subcutaneous injection, which is in Phase 1 clinical trial and profiled for its utility in the treatment of metabolic diseases. It currently has negative earnings.

Among 8 analysts covering Zafgen Inc (NASDAQ:ZFGN), 2 have Buy rating, 0 Sell and 6 Hold. Therefore 25% are positive. Zafgen Inc had 19 analyst reports since August 25, 2015 according to SRatingsIntel. The firm has “Mkt Perform” rating by FBR Capital given on Wednesday, July 20. The company was upgraded on Thursday, January 21 by FBR Capital. The stock of Zafgen, Inc. (NASDAQ:ZFGN) earned “Buy” rating by SunTrust on Monday, October 19. The firm has “Mkt Perform” rating given on Monday, October 19 by JMP Securities. FBR Capital maintained Zafgen, Inc. (NASDAQ:ZFGN) on Thursday, October 15 with “Outperform” rating. The rating was maintained by Cowen & Co on Tuesday, August 25 with “Buy”. On Wednesday, December 2 the stock rating was downgraded by RBC Capital Markets to “Sector Perform”. RBC Capital Markets maintained the shares of ZFGN in report on Thursday, October 15 with “Outperform” rating. The rating was maintained by Canaccord Genuity with “Buy” on Friday, November 13. Suntrust Robinson downgraded the stock to “Neutral” rating in Thursday, December 3 report.